(Q36604947)

15 August 2017

1 reference

title

Hypertension and antihypertensive treatment of diabetic nephropathy (English)

1 reference

15 August 2017

Eberhard Ritz

1

1 reference

15 August 2017

Ralf Dikow

series ordinal

2

1 reference

15 August 2017

publication date

1 October 2006

1 reference

Nature Clinical Practice Nephrology

15 August 2017

published in

1 reference

15 August 2017

volume

2

1 reference

15 August 2017

issue

10

1 reference

15 August 2017

page(s)

562-567

1 reference

https://scigraph.springernature.com/pub.10.1038/ncpneph0298

15 August 2017

exact match

0 references

cites work

End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Nephropathy in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Pre-diabetic blood pressure predicts urinary albumin excretion after the onset of Type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Natural history of diabetic nephropathy in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Nephropathy of type II diabetes: evidence for hereditary factors?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Familial Clustering of Cardiovascular Disease in Patients with Insulin-Dependent Diabetes and Nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

The metabolic syndrome and chronic kidney disease in U.S. adults

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Concordance between the 2005 International Diabetes Federation definition for diagnosing metabolic syndrome with the National Cholesterol Education Program Adult Treatment Panel III and the World Health Organization definitions

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Weight loss and the renin-angiotensin-aldosterone system

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Combined high blood pressure and glucose in type 2 diabetes: double jeopardy. British trial shows clear effects of treatment, especially blood pressure reduction

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Individual titration for maximal blockade of the renin-angiotensin system in proteinuric patients: a feasible strategy?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Preventing microalbuminuria in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Treatment of the patient with diabetes mellitus and risk of nephropathy: what do we know, and what do we need to learn?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Blood pressure lability and glomerulosclerosis after normotensive 5/6 renal mass reduction in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

An extremely high dose of losartan affords superior renoprotection in the remnant model

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Reversal of Glomerulosclerosis after High-Dose Enalapril Treatment in Subtotally Nephrectomized Rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Effectiveness of aldosterone blockade in patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Beneficial impact of spironolactone in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0298

7 January 2021

Identifiers

DOI

10.1038/NCPNEPH0298

1 reference

Dimensions Publication ID

15 August 2017

1002780289

0 references

1 reference